leadf
logo-loader
viewArix Bioscience PLC
(
LSE:ARIXFRA:3HY
)

Arix Bioscience investee company Amplyx announces positive Phase 2 data

Fosmanogepix was also well tolerated with no treatment-related serious adverse events or discontinuations

Arix Bioscience PLC -

Arix Bioscience PLC (LON:ARIX), the biotech venture capital company, has noted an announcement from its portfolio company Amplyx Pharmaceuticals regarding a positive result from the Phase 2 clinical trial of its novel antifungal agent, fosmanogepix.

The trial, evaluating the safety and efficacy of fosmanogepix as a first-line treatment for patients with invasive fungal infections caused by Candida, met its primary efficacy endpoint, demonstrating a treatment success rate of 80%.

Fosmanogepix was also well tolerated with no treatment-related serious adverse events or discontinuations, said Amplyx. In addition, fosmanogepix demonstrated potent in vitro activity against all Candida isolates obtained from patients in the study, including isolates resistant to other antifungal agents.

“We are very encouraged that fosmanogepix demonstrated a high rate of treatment success, including activity against resistant pathogens, and was well tolerated in patients with invasive Candida infections.

“Importantly, patients were able to easily transition from intravenous to oral formulations during their treatment,” said Michael R. Hodges, MD, chief medical officer of Amplyx.

Quick facts: Arix Bioscience PLC

Follow
LSE:ARIX

Price: 159.5 GBX

Market Cap: £207.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Redx Pharma presents at European Society for Medical Oncology (ESMO) Congress

Redx Pharma PLC's (LON:REDX) Lisa Anson joins Proactive London on the same day as the company present research at the European Society for Medical Oncology (ESMO) Congress. The firm presented the data from the phase I trial of its RXC004 monotherapy study which is their lead drug candidate,...

6 hours, 35 minutes ago

Transaction in own shares

6 hours, 9 minutes ago

Transaction in own shares

3 days, 6 hours ago

Transaction in own shares

4 days, 5 hours ago

Transaction in own shares

5 days, 6 hours ago

Transaction in own shares

6 days, 6 hours ago

Transaction in own shares

1 week, 3 days ago

Transaction in own shares

1 week, 4 days ago

2 min read